Real-World Safety and Effectiveness of a bevacizumab biosimilar (ABP 215) in Metastatic Colorectal Cancer Patients in Canada

Clinical management of metastatic colorectal cancer in the era of precision medicine

(2022) Fortunato Ciardiello et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Projected estimates of cancer in Canada in 2022

(2022) Darren R. Brenner et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study

(2022) Dirk Arnold et al.   Oncology Research and Treatment

A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada

(2020) H. Kennecke et al.   Current Oncology

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

(2020) Josep Garcia et al.   CANCER TREATMENT REVIEWS

Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer

(2020) Omar Abdel-Rahman et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Efficacy & Safety of Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Non-small Cell Lung Cancer(MAPLE):A Randomized,Double-blind,Phase 3 Study

(2019) Nicholas Thatcher et al.   CLINICAL CANCER RESEARCH

Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab

(2018) Neungseon Seo et al.   mAbs

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars

(2017) Lee S. Rosen et al.   Targeted Oncology

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

(2016) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

(2014) Lee S. Schwartzberg et al.   JOURNAL OF CLINICAL ONCOLOGY

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

(2014) Volker Heinemann et al.   LANCET ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY